Atlas Trials

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

Clinical trial NCT05345873 · UNKNOWN

Trial details

NCT number
NCT05345873
Sponsor
Sinocelltech Ltd.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19SARS-CoV-2 Infection
Start date
2022-07-01
Primary completion
2022-10-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.